Glenmark Pharmaceuticals On Friday Said It Has Received Approval From The Us Health Regulator To Market Nintedanib Capsules, Used In The Treatment Of Idiopathic Pulmonary Fibrosis And Non-Small Cell Lung Cancer, In The American Market.The Mumbai-Based Drug Major Has Received Tentative Approval From The Us Food And Drug Administration (Usfda) To Market The Product In The Strength Of 100 And 150 Mg, Glenmark Pharmaceuticals Said In A Statement.The Company'S Product Is The Generic Version Of Boehringer Ingelheim Pharmaceuticals Inc'S Ofev Capsules.According To Iqvia Sales Data For The 12 Month Period Ending April 2021, The Ofev Capsules (100 Mg And 150 Mg) Had Achieved Annual Sales Of Around Usd 1.6 Billion.Glenmark Said Its Current Portfolio Consists Of 172 Products Authorised For Distribution In The Us Marketplace And 44 Abbreviated New Drug Applications (Anda'S) Pending Approval With The Usfda.In Addition To These Internal Filings, The Drug Maker Continues To Identify And Explore External Development Partnerships To Supplement And Accelerate The Growth Of Its Existing Pipeline And Portfolio, It Added.Glenmark Has Presence Across Generics, Specialty And Otc Business With Operations In Over 50 Countries.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!